Category: Business

  • A New Dawn

    A New Dawn

    Kingsley Wheaton (Photo: BAT)

    BAT is keen to build “a better tomorrow.” Chief Marketing Officer Kingsley Wheaton explains what that entails.

    By George Gay

    I believe that Oscar Wilde, a man of fashion, once described fashion as “a form of ugliness so absolutely unbearable that we have to alter it every six months.” So I wonder whether he, as a fashionable smoker, would have supported altering the cigarette every six months, given he had known it posed an absolutely unbearable risk.

    I think he would have done so. He was a risk-taker, but he was also highly intelligent, and there comes a time when intelligent people, even risk takers, have to yield to reality. Time caught up with the tobacco industry years ago, and, during the past decade or so, it has been changing in the light of what to most people is smoking’s unacceptable risk. These changes have included offering consumers a burgeoning range of increasingly viable lower risk alternatives to combustible cigarettes, which, rather than appearing every six months, have been launched as a steady stream of innovative products that, yes, up to a point, are dictated by consumer-led fashion.

    Appropriately, Wilde talked of altering fashion while the tobacco industry talks usually of change. But there is a new word on the block: “transformation,” which seems to describe a more muscular form of change—one that is not just about the market but about the companies supplying the market and the consumers buying from the market. BAT is one company involved in transformation and, in April, Tobacco Reporter asked it what form this transformation was taking.

    “BAT has a clear purpose—to build ‘A Better Tomorrow’—by reducing the health impact of our business through offering a greater choice of enjoyable and less risky products,*” said Kingsley Wheaton, chief marketing officer, in an emailed reply. “We aim to generate an increasingly greater proportion of our revenues from products other than combustibles, and we are targeting £5 billion [$6.97 billion] New Category revenue by 2025. We aim to have 50 million consumers of our noncombustible products by 2030, and today, already 13.5 million consumers choose these products … 

    “We have the broadest New Categories portfolio in the industry, comprising vaping devices, tobacco-heating [products] and modern oral nicotine products. Our multicategory portfolio offers innovative consumer products that have been developed using cutting-edge technology and science. We are building the brands of the future.

    “From launching our first vaping device in the U.K. in 2013, our vaping products are now available in 27 countries. In total, our New Category brands are available in more than 50 countries around the world. 

    “We have come a long way, and our transformation continues to accelerate. We are building new capabilities around the world focused on science, innovation and digital technologies. Consumer preferences and technology are evolving rapidly, and we are staying ahead of the curve with our digital hubs, the creation of innovation super centers and further development of our world-class R&D laboratories. We are also leveraging the expertise of our external partners and are looking forward to exciting results from our venturing initiative BTomorrowVentures.

    “In December 2020, we also announced we had progressed our Covid-19 and seasonal flu vaccine candidates into human trials—a significant milestone that further demonstrates our commitment to innovation and science.”

    Endpoints

    It would be easy to dismiss the above reply from BAT as the sort of polished promotional prose you would expect from a multinational, and I’m certain some people will do so. But if this is your reaction, it is worth reading it again because the breadth of the transformation cannot be denied, even if you don’t like the direction of travel. As BAT pointed out, it started life in 1902 and, for more than 100 years, had a product portfolio comprising more or less only cigarettes, which themselves comprised mainly a processed plant. Now it is describing how it is harnessing science, digital technologies and innovation super centers to produce a range of new category products that will change the market and consumer habits significantly within a targeted time. And let’s not forget the vaccine trials, which are impressive in themselves, but which hint at scientific developments that might provide important cross-fertilizations.

    One interesting question that arises when considering the transformation of a company has to do with whether there comes a point at which the transformation is complete, or whether it is a continuing process without any readily identifiable endpoint.

    “From the start of our portfolio transformation journey, we have always been clear that no consumer is the same,” said Wheaton. “In order to meet differing needs in multiple marketplaces, a portfolio of suitable alternatives is required—that is the hallmark of a modern consumer products business. It’s about understanding consumer preferences and how the marketplace is evolving.

    “We are transforming from a company that defines itself by the product that we sell to the consumer needs that we meet. We are committed to driving a step change in our New Category business while also innovating new product areas that go ‘beyond nicotine.’

    “We recently entered a strategic R&D collaboration with Organigram, a leading Canadian cannabis licensed producer. This agreement augments our activities to expand our portfolio ‘beyond nicotine’ and follows the pilot launch of our first CBD vaping product, Vuse CBD Zone, in Manchester, U.K., earlier this year.”

    Advertisement

    The Shifting Regulatory Landscape

    Given the stated individuality of consumers and their inevitable turnover, it would seem that transformation will be a continuing business, especially since there is another significant variable in the equation: shifting regulatory landscapes. And at this point, the question arises as to how a multinational company can navigate regulations in a world where countries operate with different—sometimes vastly different—regulations in respect of tobacco and new-generation products.

    “The regulatory environment around tobacco harm reduction is evolving,” said Wheaton. “Science increasingly points to the reduced-risk* nature of our New Category tobacco and nicotine products as an alternative to smoking. This means we are seeing policy and regulatory shifts in several markets. Some countries have greater restrictions in place. Others, like the U.K., view tobacco harm reduction within a regulated framework, encouraging smokers to use potentially reduced-risk tobacco and nicotine products.

    “We believe a stakeholder-inclusive, whole-of-society dialogue, which includes regulators, policy makers, consumers and the industry, is key to developing effective policies that can accelerate tobacco harm reduction as fast as possible.

    “We also believe that accelerating progress toward more effective tobacco harm reduction policies needs an evidence-based approach; proportionate regulation; freedom to innovate; engagement, dialogue and communication; and responsible marketing freedoms.

    “Underpinning all of this is our ethos: It is about being bold, fast, empowered, responsible and diverse to create a future-fit culture at BAT.”

    Dropping the Pods

    Although change is always put forward as a positive by those bringing it in, it doesn’t take more than a second’s thought to realize this is not necessarily the case. And the same could be said about transformation, so Tobacco Reporter asked whether BAT was concerned the tobacco industry’s transformation to some new-generation products could be viewed as having negative consequences for the environment.

    As part of his reply, Wheaton said BAT’s group-wide circular economy strategy for all its product categories—including its New Categories portfolio—was guided by three strategic priorities:

    • Simplifying the design of products to improve recyclability and reduce the use of virgin materials and resources;
    • Maximizing the longevity of products to improve the experience for consumers; and
    • Minimizing waste through increased product recovery and recycling.

    “Responsible disposal of our New Category products is key to our approach,” he added.

    “We have implemented ‘drop the pod’ pilot schemes in France, Mexico and the U.K. for consumers to return their e-liquid pods. In Japan, we have a scheme that allows consumers to return tobacco-heating devices. We aim to implement takeback schemes for our New Category devices, in all markets where they are sold, by [the] end of 2021.”

    So it would seem that, as far as BAT is concerned, building a better tomorrow goes beyond addressing individual and societal health improvements. In answer to another question, Wheaton pointed out that the expectations of the broader society were that businesses should play a more active role in addressing and finding solutions to crucial social, economic and environmental issues. “At BAT, we welcome this shift, which is aligned to our company’s purpose and our ESG [environmental, social and corporate governance] agenda,” he said.

    “Reducing the health impact of our business by encouraging those smokers who would otherwise continue to smoke to switch completely to scientifically substantiated reduced-risk alternatives* is the greatest contribution we can make to society. This means growing our New Category business and increasing the proportion of our revenue coming from New Category products as fast as possible. 

    “Our work to reduce the environmental impact of the business will also drive growth and create shared value, delivering results that simultaneously benefit shareholders and wider society.

    “In support of our ‘A Better Tomorrow’ purpose, in 2020, we set three ambitious ESG targets: First, to increase the consumer base of our noncombustible products to 50 million by 2030; second, to become carbon neutral for emissions resulting from our own business by 2030 and accelerating our existing environmental targets to 2025; third, to eliminate unnecessary single-use plastic and make all plastic reusable, recyclable or compostable by 2025.”

    There is a saying that you can lead a horse to water, but you cannot make it drink, so what, Tobacco Reporter asked, could BAT do if a hard core of smokers decided they did not share the company’s vision of a better tomorrow? Would it keep manufacturing traditional cigarettes for them, or would it stop supplying such cigarettes when a country’s smoking population dropped below 5 percent or some such figure?

    “We are clear that cigarettes pose serious health risks,” said Wheaton. “The only way to avoid these risks is not to start or to quit. We encourage those who would otherwise continue to smoke to switch completely to scientifically substantiated reduced risk alternates.* Driving value from our combustible cigarette business is how we fuel our investment in, and transition revenue to, New Categories, so it will be an important part of our business for many years to come.

    “Providing smokers with factual information, about, for example, vaping, is essential to enable them to make informed choices. We are committed to providing this information and have launched www.vapeexplained.com, a digital information hub providing adult smokers and vapers with science-informed answers to the vaping questions most commonly searched for online. VapeExplained.com is built on the company’s vast technical expertise of over 1,500 R&D specialists and the experiences of offering vaping products in over 26 countries around the world.”

    That, of course, didn’t answer the question of how long BAT was willing to continue making combustible cigarettes for a diminishing consumer base, but an answer was hinted at in answers to the next questions, when Tobacco Reporter asked how the company would take with it on its transformation its commercial stakeholders, or, in the case of some stakeholders, such as tobacco growers, how it would help them transition to new, perhaps unrelated, activities.

    “Also on this journey to a better tomorrow, we expect tobacco growers to remain central to our supply chain for many years to come, and farmer livelihoods is one of the priority areas of our sustainability agenda,” said Wheaton. “We are committed to helping our contracted farmers and their communities to grow and flourish. Farm diversification is just one example of this.

    “Over 93 percent of our contracted farmers in our supply chain grow other crops alongside or in rotation with tobacco, ensuring they don’t rely on one crop. This has helped to increase their resilience as well as enhancing food security and preserving soil health. If there is a future impact on the overall demand for tobacco leaf, we have an established approach for working with impacted farmers to support a smooth transition into alternative agricultural livelihoods.”

    *Based on the weight of evidence and assuming a complete switch from cigarette smoking. According to BAT, these products are not risk free and are addictive. “Our products as sold in the U.S., including Vuse, Velo, Grizzly, Kodiak and Camel Snus, are subject to FDA regulation, and no reduced-risk claims will be made as to these products without agency clearance,” the company points out.

  • Japan Tobacco Reports ‘Robust’ First Quarter

    Japan Tobacco Reports ‘Robust’ First Quarter

    Photo: JTI

    The Japan Tobacco Group reported revenue of ¥547.4 billion ($5.02 billion) for the first quarter of 2021, up 5.3 percent over the revenue reported in the 2020 first quarter. Adjusted operating profit increased 21.3 percent to ¥178.1 billion while operating profit was up 24.2 percent to ¥160.1 billion. At constant currency, adjusted operating profit was ¥186.9 billion, up 27.2 percent from the 2020 quarter.

    “JT Group maintained a strong momentum in the tobacco business, mainly fueled by continued market share gains in combustibles in many markets. Furthermore, temporary and favorable industry volume trends in some mature markets resulted in a robust first quarter,” said Masamichi Terabatake, president and CEO of the JT Group, in a statement.

    JT Group maintained a strong momentum in the tobacco business, mainly fueled by continued market share gains in combustibles in many markets.

    “As announced in February, we are focusing our management resources on heated-tobacco sticks and are currently preparing the launch of Ploom X, our next-generation device in this category, in the second half of this year. Additionally, we are making steady progress as planned in developing a blueprint of our new operating model and organizational structure for a combined tobacco business from 2022.

    “With our robust first-quarter performance, we aim to achieve our full-year forecast. However, we cannot ignore the uncertainties that the Covid-19 pandemic poses, so we will continue to closely monitor the changing operating environment.”

    For the full-year 2021, the JT Group expects revenue to decrease by 0.6 percent to ¥2.08 trillion. Consolidated adjusted operating profit at constant currency is expected to increase by 5.1 percent to ¥512 billion.

    On a reported basis, adjusted operating profit is forecast to decrease by 2.5 percent to ¥475 billion. Operating profit is forecast to decrease by 22.6 percent to ¥363 billion.

  • Pyxus Secures Working Capital Funding

    Pyxus Secures Working Capital Funding

    Photo: Pyxus International

    Pyxus International announced that one of its indirect subsidiaries has entered into a term loan credit agreement with the company and certain of its other subsidiaries as guarantors, with certain funds managed by Glendon Capital Management and Monarch Alternative Capital as lenders and Alter Domus (U.S.) as administrative agent and collateral agent.

    The credit agreement establishes a $120 million delayed-draw term loan credit facility with a maturity date in July 2022.

    “Covid-19 has caused delays in shipment of leaf tobacco, which, as a result, has pushed fulfillment of certain customer orders from the fourth quarter of fiscal 2021 into fiscal 2022,” said Pieter Sikkel, president and CEO of Pyxus International, in a statement.

    “The combination of these delays along with increasing customer demand for 2021 crops has created the need for a short-term financing to fund working capital. We anticipate a portion of this loan will be repaid once Covid-19-related delays have been resolved, though a portion may be left outstanding to fund increased purchases of this year’s crop in line with our improving sales expectations.”

  • Altria Reports First-Quarter 2021 Results

    Altria Reports First-Quarter 2021 Results

    Photo: Kristina Blokhin

    Altria Group reported net revenues of $6.03 billion in the first quarter of 2021, down 5.1 percent from the comparable 2020 quarter. The decline was driven primarily by lower net revenues in the smokable products segment.

    Net revenues net of excise taxes were $4.88 billion, 3.3 percent lower than in last year’s quarter. Reported diluted earnings per share declined 7.2 percent to $0.77, primarily driven by losses on early extinguishment of debt from a debt liability management transaction, a decrease in the estimated fair value of Altria’s investment in Juul and higher acquisition-related costs, partially offset by higher reported operating companies’ income (in the wine segment and favorable Cronos-related and ABI-related special items).

    “We are off to a strong start to the year and believe our businesses are on track to deliver against full-year plans. Against a challenging comparison, our tobacco businesses performed well in the first quarter and we continued to make progress advancing our noncombustible portfolio,” said Billy Gifford, Altria’s CEO, in a statement.

    “This morning, we announced another important milestone in Altria’s journey in ‘moving beyond smoking.’ We now have full global ownership of On! oral nicotine pouches as we recently closed transactions to acquire the remaining 20 percent global interest.”

    “We would like to honor the memory of Tom Farrell, our late chairman of the board. Tom served 13 distinguished years on our board, offered valuable insights and guidance during his tenure and was a true visionary. We will miss his leadership, contributions and friendship.”

    In March, Altria Group announced that Thomas F. Farrell II would retire from the company’s board of directors following the completion of his current term. Farrell has been a director of Altria since 2008.

  • Taat Lifestyle now Taat Global Alternatives

    Taat Lifestyle now Taat Global Alternatives

    Photo: Taat Global Alternatives

    Taat Lifestyle & Wellness will change its name to Taat Global Alternatives effective as of the commencement of trading on April 28, 2021.

    There will be no change to the symbol, and the company’s common shares will continue to trade under the ticker “TAAT” on the Canadian Securities Exchange.

    “Now that we have gained momentum in the $814 billion global tobacco industry, we have determined it to be important to ensure the most prominent identifying attributes of the company reflect our mission and business objectives,” said Setti Coscarella, Taat CEO, in a statement. “Last week, we announced our Beyond Nicotine initiative based on reports that the Biden administration plans to take action to reduce nicotine content in tobacco cigarettes sold in the United States.

    “Our value proposition is built around offering a better alternative for smokers aged 21-plus, giving them the choice to keep the experiences they enjoy while leaving nicotine behind. With over 1.3 billion users of tobacco worldwide, we believe Taat and its Beyond Tobacco base material are relevant globally, which led to our board of directors agreeing on the updated name.”

    Earlier this week, Taat applied for a Nasdaq listing.

  • Stora Enso Releases Interim Report

    Stora Enso Releases Interim Report

    Stora Enso’s headquarters in Helsinki

    Stora Enso reported sales of €2.28 billion ($2.75 billion) in the first quarter of 2021, up 3 percent from the previous year’s quarter due to higher deliveries and prices. Operational earnings before interest and tax (EBIT) increased to €328 million due to lower costs. Operational EBIT margin increased to 14.4 percent from 8.1 percent. Operating profit (IFRS) decreased to €161 million.

    Cash flow from operations amounted to €185 million. Cash flow after investing activities was -€9 million. The net debt to operational earnings before interest, taxes, depreciation and amortization EBITDA ratio was 2.3.

    “For the year’s first quarter, I am pleased to deliver yet another solid result, and we are getting back on track with many of our financial targets,” said Stora Enso President and CEO Annica Bresky in a statement.

    “For the full year, the demand outlook continues to be healthy for all businesses except for paper. The operational EBIT in 2021 is expected to be higher than in 2020. We are ahead of plan with our €400 million profit protection program, and it will be concluded already by the end of the second quarter 2021.”

    Earlier this month, Stora Enso announced a plan to permanently cease pulp and paper production at its Kvarnsveden and Veitsiluoto mills due to overcapacity resulting from declining demand.

    “Closing operations that impact our staff is always a last resort, and one based on thorough evaluations,” said Bresky. “However, in order to remain competitive in a rapidly declining paper market, the closing of unprofitable assets is needed.”

  • UKVIA Surveys Vapor Industry About Logistics

    UKVIA Surveys Vapor Industry About Logistics

    Photo: Andrey Popov

    The U.K. Vaping Industry Association (UKVIA) has launched an online logistics survey for the vaping industry.

    This action follows the decision of several delivery companies to stop carrying shipments of vaping products.

    Reports have involved leading providers such as DHL, UPS and FedEx, resulting in varying degrees of disruption to deliveries in recent months. The UKVIA is keen to learn if any disruption is affecting products imported from countries within the European Union or if products imported from China and the USA are also being held up.

    “The UKVIA is extremely concerned to hear of any disruption to deliveries of vaping products experienced by our members or any other businesses in the sector,” said John Dunne, director general of the UKVIA.

    “We will be closely looking into the response to this survey to gauge the severity of the problems faced by businesses. The UKVIA will then be in a better position to take up these concerns on behalf of our members and the wider industry. I would encourage everyone eligible to take part in the survey or to get in contact with the UKVIA directly to flag up any individual logistics issues.”

    The survey is at www.surveymonkey.co.uk/r/2YYZYJW.

  • Taat Lifestyle Applies for Nasdaq Listing

    Taat Lifestyle Applies for Nasdaq Listing

    Taat CEO Setti Coscarella
    Setti Coscarella

    Taat Lifestyle & Wellness has submitted an initial application for its common shares to be listed on the Nasdaq Capital Market in the United States.

    Last month, the company’s common shares had been upgraded from the OTCQB Venture Market to the OTCQX Best Market.

    “Ever since Taat became publicly traded on June 22, 2020, we have made great strides in our efforts to gain market share in the $814 billion global tobacco industry,” said Taat CEO Setti Coscarella in a statement.

    “Between listings in American and European markets as well as our rapid ascension of the ranks in the OTC markets, I believe we have consistently strengthened our value proposition to investors around the world as a firm positioned to create long-term value in providing a better alternative to tobacco cigarettes for smokers aged 21-plus.

    “We look forward to working with Nasdaq Inc. in navigating this application process, as I believe being listed on the Nasdaq Capital Market could considerably strengthen our long-term prospects as a public company.”

    Marissa Dean profiled Taat in Tobacco Reporter’s January 2021 edition.

  • Analysts: Nicotine Reduction Takes Time

    Analysts: Nicotine Reduction Takes Time

    Photo: Maksym Yemelyanov

    Industry analysts expect the implementation of any plan to mandate lower nicotine levels for cigarettes sold in the U.S. to take a long time.

    Tobacco stocks plunged on April 19 after The Wall Street Journal published an article suggesting the Biden administration is considering a policy that would require tobacco companies to reduce nicotine levels in cigarettes to nonaddictive levels.

    Industry analysts, however, said this process will be lengthy, according to an article published by CSP.

    “While we see a very long and uncertain road to establishing a legally enforceable nicotine standard, we believe there is heightened headline risk, and the likelihood for a nicotine standard to ultimately be implemented exists,” Bonnie Herzog, a managing director of Goldman Sachs, said in a research note.

    If the Biden administration moves forward with its plan, Herzog said she would expect cigarette volumes to decline dramatically and more people to convert to reduced-risk products and technologies.

    Nik Modi, analyst at New York-based RBC Capital Markets, said in a research note that he’s cautious of becoming too invested in potential consequences at this time because nicotine regulation is just a consideration.

    If the regulation moves to the next step, the U.S. Food and Drug Administration (FDA) would have to release a notice of proposed rulemaking and consider potential consequences. At a minimum, there is a mandatory one-year to two-year delay between issuing a final rule and policy implementation, Herzog said.

    Among other things, the agency would have to consider whether lowering nicotine levels would increase consumption of cigarettes because of reduced-risk perceptions, and if its policy would boost black market sales or unregulated home manufacturing.

    At a minimum, there is a mandatory one-year to two-year delay between issuing a final rule and policy implementation.

    Commentators have already warned against unintended consequences of a low-nicotine mandate. Such a policy would stimulate illicit trade and could result in more smoking-related illness, wrote Brad Polumbo, a policy correspondent at the Foundation for Economic Education (FFEE).

    “Were the amount of nicotine in cigarettes lowered by law, many people would respond by smoking more total cigarettes to get their nicotine fix. Because it is tar and other carcinogenic substances in cigarettes that cause cancer—not the nicotine itself—this would likely mean more cases of lung cancer and more premature deaths,” he wrote on the FFEE website.

    What’s more, smokers unhappy with the new weak cigarettes for sale at legal outlets may turn to black markets to buy stronger variants, according to Polumbo. “Because black market dealers have little business accountability or oversight, there’s a greater chance that the products could be laced with dangerous substances or dangerously made,” he wrote.

    The argument of compensatory smoking is disputed by 22nd Century Group, a company specializing in low-nicotine tobacco that stands to gain considerably from a nationwide low-nicotine mandate.

    “Public health researchers have conclusively refuted the common misperception that reduced-nicotine content cigarettes could cause smokers to increase their smoking, saying, ‘Effectively compensating to maintain nicotine exposure is virtually impossible when switching to cigarettes with minimally addictive nicotine content,’ and, ‘[M]andated reduction in nicotine content is unlikely to result in an increase in smoking behavior to obtain more nicotine,’” the company wrote in a statement about the topic.

    Nik Modi

    Analysts also noted that policy implementation could be delayed by legal challenges from the tobacco industry. Cigarette manufacturers could challenge or sue the FDA if they think the agency isn’t acing in accordance with regulatory guidelines or overstepping boundaries, said Modi.

    The current discussion about lowering nicotine dates from 2018, when the FDA introduced its Comprehensive Plan for Tobacco and Nicotine Regulation.

  • Charlie’s Pachamama Sell Out in 21 Days

    Charlie’s Pachamama Sell Out in 21 Days

    Brandon Stump
    (Photo: Charlie’s Holdings)

    Charlie’s Holdings has sold its entire initial stock of Pachamama Disposables e-cigarettes in fewer than 21 days, making Pachamama the fastest-selling new product in the company’s history, according to a press release.

    “It is estimated that more than 20 percent of the world’s population consumes nicotine in some format,” said Brandon Stump, CEO of Charlie’s Holdings. “We believe that our new technologies and products can provide adult consumers with a better, more responsible and therefore more enjoyable means of experiencing nicotine.

    “Now that we have launched Pachamama Disposables in the United States, later this year, our distribution will expand into more than 75 international markets, where we expect to introduce millions of adult consumers to the extraordinary Pachamama sensory experience. We are very excited about what this launch—and the new $600 million market opportunity—will mean for our customers and our company.”

    We are very excited about what this launch—and the new $600 million market opportunity—will mean for our customers and our company.

    Earlier this month, Charlie’s Holdings raised $3 million through the private sale of common stock to the company’s founders, Brandon Stump and Chief Operating Officer Ryan Stump. The company intends to use the proceeds from the offering to drive substantial future growth, facilitate new product launches, increase working capital, retire outstanding debt and for other general corporate purposes.

    The proceeds from the private placement will strengthen the company’s balance sheet, accelerate European growth, allow for expansion into the Middle East and facilitate the company reaching several important near-term milestones, including FDA approval of Charlie Holdings’ premarket tobacco product application.